Scientists Upgraded CRISPR Using Only Computers, and It Actually Works
Researchers have designed an improved version of the CRISPR gene-editing tool that can reach more locations in the genome, and they did it entirely through computer simulations, without running a single wet-lab experiment first. The result holds up.
CRISPR-Cas9 is the molecular scissors that geneticists use to cut DNA at precise locations. But the tool has a constraint: it can only cut at sites preceded by a short recognition sequence in the DNA called a PAM motif. Without the right motif in the right place, CRISPR cannot find its target. That sounds technical, but the practical implication is significant: a substantial portion of the human genome is currently out of reach for editing.
One widely used variant for applications in living organisms is Staphylococcus aureus Cas9, or SaCas9. It is smaller than the more familiar version and therefore fits more easily into the viral delivery vehicles used to transport the system into cells, a critical property for therapeutic use. But SaCas9 has a strict PAM requirement that severely limits the number of usable sites in the genome.
Designing without test tubes
The researchers used an entirely computational approach, a platform they call UniDesign, to predict which mutations in the protein would relax the PAM requirement without disrupting the rest of its function. That produced a variant they named KRH. When subsequently tested in the laboratory, KRH performed as predicted: a broader range of DNA sequences was accessible, while the precision of the editing remained intact.
The methodology itself may be as significant as the outcome. Traditionally, protein variants are developed through iterative experimentation: design a mutant, test it, adjust, test again. That process is slow and expensive. A fully computational design that works on first laboratory contact suggests that models for protein structure and function have crossed a meaningful threshold.
What this means for gene therapy and longevity
For longevity research, the implications run on several levels. Gene therapy, correcting faulty genes or introducing new instructions into cells, has long promised to be transformative, but keeps running into practical barriers: which cells can you reach, how large is your tool, how precisely can you cut? A compact Cas9 variant with a relaxed PAM requirement removes one of those barriers.
More concretely, genes associated with aging or age-related disease become more accessible for precision editing. Whether that quickly translates into clinical applications is a separate question. The distance between an improved laboratory tool and a safe, approved human therapy remains substantial. But the direction of travel is clear.